AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03640273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 Mg
Description: Take Loratadine 10 mg once a day before meals.
Study NCT00835016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early psychosocial stimulation (LTP)
Description: Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
Study NCT00835016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early psychosocial stimulation (LTP)
Description: Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
Study NCT01942083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Study NCT03429387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Description: FDG-PET performed with low dose CT
Study NCT05428072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar test
Description: All participants will take two sugar tests ( sugar cocktail consisting of mannitol \& lactulose) subjects within 2-3 days of the initial sugar test.
Study NCT05428072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Challenge
Description: All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 \& 1 hour before the sugar drink.
Study NCT03429387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CT
Description: HRCT and CT of sinuses +/- other regions as per clinician's discretion
Study NCT02414230 — intervention group
Intervention type: DRUG
Intervention: Drug: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study NCT01720446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
Study NCT00694512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low fat diet
Description: 20% fat diet
Study NCT00694512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High fat diet
Description: 40% fat diet
Study NCT00694512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT diet
Description: Medium chain triglyceride diet
Study NCT02244450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCID screening
Study NCT00808691 — intervention group
Intervention type: OTHER
Intervention: Critical care
Description: Standard care for each group of patients
Study NCT01720446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
Study NCT01720446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
Study NCT01379534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study NCT04285346 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ganaxolone
Description: titration followed by maintenance and extension period
Study NCT06269341 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03823417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
Study NCT03823417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion
Study NCT05118958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 1 modified-release tablet
Description: 300 mg modified-release tablet
Study NCT01004328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1: Electronic medical record (EMR)-based transitional care intervention
Description: Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
Study NCT03837769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia OBPM PulseWatch wrist device
Description: The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Epic Basic Alert
Description: This alert will be representative of the alerts currently firing in the Atrius system and not incorporate any functionality.
Study NCT00853424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: islet cell transplant
Description: Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
Study NCT00853424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: subjects receive all recommended medical treatment for diabetes and diabetic eye disease
Study NCT05118958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 2 modified-release tablet
Description: 300 mg modified-release tablet
Study NCT05118958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KVD824 Immediate-Release Capsule
Description: 300 mg immediate-release capsule
Study NCT00452465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ElderCare Plan
Description: Nursing assessment and development of an appropriate care plan.
Study NCT04726046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotetan
Description: Cefotetan (as Disodium) 1 GM Injection before surgery
Study NCT00067639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (Neulasta)
Description: 12 mg single injection of pegfilgrastim under the skin prior to apheresis.
Study NCT00067639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
Study NCT05118958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to KVD824 Prototype 1
Description: Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
Study NCT04284553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Alert
Description: An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
Study NCT03898531 — intervention group
Intervention type: PROCEDURE
Intervention: hip prosthesis removed metal / polyethylene, simple mobility
Description: Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation
Study NCT03898531 — intervention group
Intervention type: PROCEDURE
Intervention: hip prosthesis removed metal / polyethylene, double mobility
Description: Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation
Study NCT03898531 — intervention group
Intervention type: PROCEDURE
Intervention: hip prosthesis removed ceramic/ polyethylene, simple mobility
Description: Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation
Study NCT03898531 — intervention group
Intervention type: PROCEDURE
Intervention: hip prosthesis removed ceramic/ polyethylene, double mobility
Description: Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation.
Study NCT03898531 — intervention group
Intervention type: PROCEDURE
Intervention: Primary implanted hip prosthesis
Description: Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis.
Study NCT03898531 — intervention group
Intervention type: PROCEDURE
Intervention: hip prosthesis removed metal/metal
Description: Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation
Study NCT03898531 — intervention group
Intervention type: PROCEDURE
Intervention: hip prosthesis removed ceramic/ceramic
Description: Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation
Study NCT03494686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLETZ under local anaesthesia
Description: Conization will be performed under local anaesthesia
Study NCT03494686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ under general anaesthesia
Description: Conization will be performed under general anaesthesia
Study NCT01947309 — intervention group
Intervention type: DRUG
Intervention: Revlimid (lenalidomide)
Description: Revlimid (lenalidomide) as prescribed in usual clinical practice
Study NCT01751880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity intervention
Description: Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
Study NCT01659294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Case Management
Study NCT01659294 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard diabetologist care
Description: routine care by diabetologist \& team
Study NCT05349604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Garlic extracts
Description: One intake in total
Study NCT01259765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VHH batch 203027
Description: The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
Study NCT01259765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
Study NCT03100097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen Horizon 627 LSO
Study NCT05118958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD824 Prototype 3 modified-release tablet
Description: 300 mg modified-release tablet
Study NCT00231842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
Study NCT00231842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
Study NCT02773914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Comprehensive Geriatric Assessment intervention
Study NCT03582033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-BCMA
Description: Given into the vein (IV; intravenously)
Study NCT03582033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given by mouth (orally) or by IV
Study NCT00231842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
Study NCT03582033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Given orally
Study NCT04417621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXH254
Description: LXH254 will be supplied as tablet for oral use.
Study NCT04417621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTT462
Description: LTT462 will be supplied as hard gelatin capsule for oral use.
Study NCT04417621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be supplied as film-coated tablet for oral use
Study NCT04417621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib will be supplied in tablets and hard gelatin capsules.
Study NCT04159610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WO3970
Description: Application of cream to each axilla
Study NCT04159610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
Description: Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
Study NCT03350516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily 500 mg elemental calcium as calcium carbonate
Description: Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
Study NCT03350516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daily1500 mg elemental calcium as calcium carbonate
Description: Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
Study NCT02633995 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anaesthesia
Description: regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
Study NCT05473637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Patients will repeat study-protocol MRI at baseline (enrollment) and at least once in 1 year or 2 years follow-up (depends on availability).
Study NCT06691880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindPod Dolphin VGT
Description: The MindPod Dolphin, is an interactive video game that allows users to engage in non-task-based tasks to motivate the users to play and relearn motor skills. The MindPod gaming platform uses markerless tracking to sense the patient's affected arm. The paretic limb controls Bandit the dolphin underwater in an effort to eat fish. The patient learns to map his/her movements to Bandit in a 3-Dimensional work space to reach the targets. During gaming, the therapist titrates game difficulty. Bilateral gaming components are used (the participant uses a controller with the participant's less-affected limb to control the timing of Bandit's movement) and in-game difficulty can be adjusted to create an immersive, challenging, and engaging experience. In order to be successful, the patient must coordinate both arms to control the temporal and spatial aspects of the game.
Study NCT06691880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual Arm Trainer VGT
Description: The bimanual arm trainer (BAT) is a device that involves hardware that interfaces with a computer game. The BAT promotes shoulder external rotation and elbow extension in the paretic arm by coupling movements of the paretic arm with the less affected limb as the participant matches his/her arm movements to those of a virtual avatar. The less-affected side and paretic limb are placed in the BAT apparatus and the less affected limb drives the impaired limb through passive, symmetrical movements that simulate rowing down a virtual river. The protocol created by the investigators group, leads the patient through an active-passive training progression similar to paradigms used in neural priming studies. Through these series of movements, the goal is to restore balance between the muscles of the upper back and chest to maximize range of motion in preparation for improved quality of movement.
Study NCT06692387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step count increase with the use of a motivational application
Description: The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.
Study NCT06692387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count increase with the use of a motivational application
Description: The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.
Study NCT00968019 — intervention group
Intervention type: DEVICE
Intervention: Presillion stent
Description: Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
Study NCT02349074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digestive endoscopy
Description: Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
Study NCT00685035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFCWC with higher pressure/variable-frequency settings
Description: Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.